The Steno-2 study and UKPDS showed that targeted intensified intervention on modifiable cardiovascular risk factors in patients with type 2 diabetes reduces morbidity and mortality. The Alphabet POEM strategy (Practice Of Evidence-based Medicine) assessed the effect of systematic application of the Alphabet Strategy to care of patients with type 2 diabetes. In comparison to the Steno-2 intensive cohort, Alphabet POEM fared similarly with regard to diastolic blood pressure (BP), HbA1C, aspirin and angiotensin-converting enzyme (ACE) inhibitor use, but less well with respect to systolic BP, total cholesterol and use of statins. Alphabet POEM achieved better systolic and diastolic BP than UKPDS but glycaemic control was significantly worse. The standards achieved in the Steno-2 study and UKPDS are in principle, at least, partially achievable in a district general hospital in the UK, but fully achieving them in practice will probably need a radical restructuring, and greater provision of resources.
Bhopal RS, Unwin N., White M. et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study . BMJ1999;319:215-20.
2.
King H., Aubert RE, Herman WHGlobal burden of diabetes 19952025: prevalence, numerical estimates and projections . Diabetes Care1998;21:1414-31.
3.
Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, I: all-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med1999;16:459-65.
4.
Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med1999;16:466-71.
5.
Rosengren A. , Welin L., Tsipogianni A., Wilhelmsen L.Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ1989;299:1127-31.
6.
Currie CJ, Kraus D., Morgan CL, Gill L., Stott NC, Peters JRNHS acute sector expenditure for diabetes: the present, future, and excess in-patient cost of care. Diabet Med1997;14:686-92.
7.
National Service Framework for Diabetes: Delivery Strategy. Department of Health, 2002.
8.
Levy JCUKPDS Odyssey. Br J Diabetes Vasc Dis2001 ;1:14-21.
9.
Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial: HOT study Group. Lancet1998;351:1755-62.
10.
Department of Health.National Service Framework for Coronary Artery Disease. Modern Standards and Service ModelsLondon: Department of Health2000.
11.
Gaede P., Vedel P., Larsen N., Jensen GV, Parving HH, Pedersen O.Multifactorial Intervention and cardiovascular disease in patients with type 2 Diabetes. N Engl J Med2003;348:383-93.
12.
Gaede P., Vedel P., Parving HH, Pedersen O.Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the steno type 2 randomised study. Lancet1999;353:617-22.
13.
Patel V., Morrissey J.The Alphabet Strategy: the ABC of reducing diabetes complications . Br J Diabetes Vasc Dis2002;2:58-9.
14.
US Preventive services Task Force: Counseling to prevent tobacco use. In Guide to clinical Preventive Service. 2nd ed. Baltimore, MD: Williams & Wilkins1996:597-609.
15.
Daly LE, Mulcahy R., Graham IM, Hickey N.Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. BMJ1983;287:324-6.
16.
Balkau B., Shipley M., Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20 year follow-up in the Whitehall study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care1998;21:360-7.
17.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998;317:703-13.
18.
Aspire Steering Group.A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Principal results. Heart1996;75:334-42.
19.
Pyorala K., Perdersen TR, Kjeksus J. et al. cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian simvastatin study (4S). Diabetes Care1997;20:614-20.
20.
Sacks FM, Pfeffer MA, Moye LA et al. for the cholesterol and recurrent events trial investigators: The effect of Pravastatin on coronary events after myocardial infraction 1 Patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators . N Engl J Med1996;335:1001-09.
21.
Long-Term intervention with Pravastatin in Ischaemic disease (LIPID) study group.Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and q broad range of initial cholesterol levels: the Long - Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med1998;339:1349-57.
22.
Shepherd J. , Macfarlane PW, Blauw GJ et al. on behalf of the PROSPER study group.Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomised controlled trial. Lancet2002;360:1623-30.
23.
Causes of blindness and partial sight in England and Wales,1990-1991, J Evans, 1995. Office of population Censuses and Surveys, Studies on Medical and Population Subjects, No.57. London: HMSO.
24.
Rohan TE, Frost CD, Wald NJPrevention of blindness by screening for diabetic retinopathy: a quantitative assessment. BMJ1989;299:1198-201.
25.
Young MJ, Breddy JL, Veves A., Boulton AJThe prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care1994;17:557-60.
26.
Bild DE, Selby JV, Sinnock P., Browner WS, Braveman P., Showstack JALower-extremity amputation in people with diabetes: epidemiology and prevention . Diabetes Care1989;12(1):24-31.
27.
Collaborative overview of randomised trials with antiplatelet therapy.Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ1994;308: 81-106.
28.
Heart Outcomes Prevention Evaluation (HOPE) study investigators: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet2000;355:253-9.
29.
The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT).Major outcomes in high-risk hypertensive patients Randomized to Angiotensin-converting enzyme inhibitor or calcium channel blocker vs Diuretic. JAMA Express2002;288:2981-94.
30.
Lindholm LH , Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359:1004-10.
31.
Mogensen CE , Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependant diabetes. The candesartan and lisinopril microalbuminuria (CALM Study). BMJ2000;321:1440-4.
32.
New JP, Roxburgh RA, Vaughan NJ, Wallace C., Elliott P., Young RJMeasuring differences in the provision of diabetes care. Diabetes Nutr Metab2001;14:104-07.
33.
Gæde P. , Vedel P., Larsen N., Jensen GVH , Parving H-H., Pedersen O.Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med2003;348:383-93.
34.
Spooner A., Chapple A., Roland M.What makes British general practitioners take part in a quality improvement scheme?J Health Serv Res Policy2001;6:145-50.
